Fibrin binding domain polypeptides and uses and methods of producing same
View Patent ↗This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides. The invention also provides for purified polypeptides substantially free of other substances of human origin which have an amino acid sequence substantially present in the fibrin binding domain of naturally-occurring human fibronectin and which are capable of binding to fibrin.
1. An imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence which comprises at least one fifth of the amino acid sequence of the N-terminal fibrin binding domain of naturally occurring fibronectin, commencing from the fourth amino acid shown in SEQ ID NO: 15, wherein the N-terminal fibrin binding domain comprises 262 amino acids commencing from the fourth amino acid shown in SEQ ID NO: 15, and wherein the polypeptide optionally has a methionine at its N-terminus, and wherein the polypeptide has a molecular weight less than 31 kD.
2. The agent of claim 1 , wherein the marker is a radioactive isotope, an element which is opaque to X-rays, or a paramagnetic ion.
3. The agent of claim 2 , wherein the marker is a radioactive isotope.
4. A purified polypeptide having an amino acid sequence which comprises at least one fifth of the amino acid sequence of the N-terminal fibrin binding domain of naturally-occurring fibronectin commencing from the fourth amino acid shown in SEQ ID NO: 15, wherein the N-terminal fibrin binding domain comprises 262 amino acids commencing from the fourth amino acid show in SEQ ID NO:15, and wherein the polypeptide optionally has a methionine at its N-terminus, and wherein the polypeptide has a molecular weight less than 31 kD.